2021 Fourth Annual National Conference

September 9-11, 2021

Red Rock Hotel – Las Vegas, NV

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Gastroenterology and Hepatology Advanced Practice Providers.
Chronic hepatitis C: Access to treatment and elimination strategies

Michelle Barnett, PA-C, DFAAPA
Associates in Gastroenterology
Colorado Springs, Colorado

Allison Hobbs, MSN, APRN- C
UofL Health
Louisville, Kentucky
Disclosures

All individuals involved in control of the content of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All staff at the Annenberg Center for Health Sciences at Eisenhower and Gastroenterology and Hepatology Advanced Practice Providers have no relationships to disclose.
Disclosures

Michelle Barnett, PA-C, DFAAPA
Speaker Bureau: Gilead, Clinical Area – HCV
Speaker Bureau: AbbVie, Clinical Area – HCV
Advisory Board: Salix, Clinical Area – GI/SIBO

Allison Hobbs, APRN-C
Advisory Board: Gilead, Clinical Area – HCV
Objectives

• Updated HCV epidemiology (United States)

• Understand treatment availability

• Recognize World Health Organization Elimination Goals

• Delineate micro-elimination strategies

• Identify barriers to micro-elimination

• Understand the importance of harm reduction in micro-elimination
Global Prevalence of Chronic HCV Infection

GLOBAL
58 million
[46 million–76 million]

REGION OF THE AMERICAS
5 million
[4 million–5 million]

EUROPEAN REGION
12 million
[10 million–14 million]

WESTERN PACIFIC REGION
10 million
[8 million–14 million]
Figure 3.4. Rates of reported acute hepatitis C virus infection, by age group — United States, 2004–2019

Source: CDC, National Notifiable Diseases Surveillance System.
Acute Hep C Cases

Why are HCV cases on the rise?
• Opioid Crisis

Burden of HCV in the US

- Hepatitis C virus (HCV) kills more Americans than the 60 other reportable infectious diseases, including HIV, combined
- Baby boomers (born between 1945 and 1965), especially African Americans, face high burdens of chronic HCV infection
- People who inject drugs face rapidly rising rates of acute HCV infection as a result of the growing opioid epidemic
- This is a pivotal moment in HCV treatment, because curative treatment regimens are now available
  - These treatments are significantly more effective, rapid, and tolerable than prior regimens
  - With curative treatment, eliminating HCV as a public health threat is a real possibility

Rate of HCV Death Varies by State

Centers for Disease Control and Prevention. Division of Viral Hepatitis. Statistics and Surveillance.
Benefits of Treatment & Cure

- **Curative treatment reduces:**
  - Risk of liver cancer by 75%
  - Risk of all-cause mortality by 50%
- **Curative treatment improves:**
  - Cost-effectiveness compared to past treatment regimens
  - Cost-effectiveness compared to long-term treatment of HCV-associated conditions
  - Patient quality of life
- **Curative treatment prevents** future transmission of HCV
  - Rates of reinfection among persons who inject drugs are relatively low, especially with behavioral support, and should not be a justification for withholding curative treatment

AASLD/IDSA Guidance: Simplified Pretreatment Assessment

- **Within 6 mos prior to initiating treatment**
  - Complete blood count (CBC)
  - International normalized ratio (INR)
  - Hepatic function panel (liver function tests)
  - Estimated glomerular filtration rate (eGFR)

- **Anytime prior to starting antiviral therapy**
  - Quantitative HCV RNA (HCV viral load)
  - HCV genotype—only if a nonpangenotypic DAA will be prescribed
  - Other viral tests: HIV antigen/antibody test and HBsAg
  - Check for drug–drug interactions with DAA therapy
Treatment cascade for chronic HCV infection

Yehia et al., 2014.
Access to Treatment: Restrictions 2021

Hepatitis C treatment restrictions have **lessened** over the last decade since the introduction of **direct-acting antivirals** (DAAs). Fewer treatment restrictions allow for increased access to Hepatitis C treatment for patients in Medicaid programs.

### Current Hepatitis C Treatment Restrictions for Medicaid, 2021

<table>
<thead>
<tr>
<th>Status</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>32 states</strong></td>
<td>have eliminated or reduced fibrosis restrictions, 4 remain.</td>
</tr>
<tr>
<td><strong>21 states</strong></td>
<td>have loosened sobriety restrictions, 28 remain.</td>
</tr>
<tr>
<td><strong>25 states</strong></td>
<td>have scaled back prescriber restrictions, 18 remain.</td>
</tr>
</tbody>
</table>

*Statuses are as of April 2021. *For purposes of analysis, District of Columbia and Puerto Rico are treated like states.*
As of April 2021, **more than half** of U.S. states* have **sobriety restrictions** for Hepatitis C treatment.

Some sobriety restrictions require individuals to abstain from using alcohol and/or drugs for a specified timeframe prior to starting Hepatitis C treatment.

*For purposes of analysis, District of Columbia and Puerto Rico are treated like states.*
As of April 2021, **48 states** have **no fibrosis** (liver scarring) **restrictions** for Hepatitis C treatment.

**Nebraska, Texas, Arkansas, and South Dakota** still have fibrosis restrictions.

Fibrosis restrictions **require patients to wait** until Hepatitis C damages their liver before receiving Hepatitis C treatment.

*For purposes of analysis, District of Columbia and Puerto Rico are treated like states.*
HCV Access to Treatment: HCV Continuum of Care Among PWID

- Random sample of newly reported HCV antibody positive persons (Philadelphia Center for Public Health n=29,820; 2013-2017)
- Measurable gaps exist in the HCV continuum of care for PWIDs, especially those ≤35 years of age
  - Only 29% and 10% of PWIDs >35 and ≤35 years of age, respectively, were treated
- Need for enhanced navigation to services
HCV Access to Treatment: State Programs

“Netflix Model”
• Louisiana
• Washington
  – Programs include testing and linkage-to-care services
  – Broad access to treatment

Telehealth/Telementorship Models
• Veterans Affairs
• Project ECHO (Extension for Communities Healthcare Outcomes)
• Kentucky Hepatitis Academic Mentorship Program (KHAMP) & US-HAMP
Project ECHO: Physician Peer Support for Expanding Access to HCV Treatment

- First developed by University of New Mexico in 2003 to build primary care capacity to treat HCV infections in rural, underserved populations
- Video conferences link interdisciplinary specialist teams with primary care providers for longitudinal co-management
- ECHO sessions include:
  - Brief didactic
  - Case presentations
  - Discussion with community of learners
- Physician survey data demonstrated significant increases in provider knowledge, self-efficacy, and professional satisfaction

Slide credit: clinicaloptions.com
HCV Elimination Strategies

HCV Elimination: Why?

In the United States alone, studies suggest that a fourfold increase in treatment of hepatitis C (from about 100,000 to 400,000 patients per year) could prevent more than 250,000 deaths and more than 500,000 cases of cirrhosis per year.

Durham et al., 2016.
# HCV Elimination: World Health Organization

## Table of Contents

- Executive summary .......................................................... 2
- A. Mortality from viral hepatitis is on the increase because of poor access to treatment .................................................. 4
- B. Combining treatment with prevention could eliminate viral hepatitis as a public health problem by 2030 ........................................ 6
- C. Prevention is effective and cost-effective, but needs to reach the unreached .......................................................... 7
- D. There is now a solid case to scale up testing and treatment: treatment works and can save lives within a short time horizon .......... 8
- E. Treating HBV and HCV coinfection among HIV-infected persons helps secure the health gains from HIV treatment ................. 12
- F. Economic analysis .......................................................... 12
- G. WHO’s role ................................................................. 14

References ........................................................................ 16
HCV Elimination: World Health Organization

“A world where viral hepatitis transmission is stopped and everyone has access to safe, affordable and effective treatment and care”

WHO 2030 Targets
- 90% HCV Diagnosed
- 80% Treated
- 80% Reduction in new HCV infections
- 65% Reduced HCV-related mortality

“Elimination” = 90% reduction in incidence by 2030

Important to remember ➔ Elimination does not equal Eradication

Impact targets for elimination

90% reduction in new cases of chronic HBV and HCV infection

65% reduction in deaths from chronic HBV and HCV

6-10 million infections (in 2015) to <900,000 infections (by 2030)

1.4 million deaths (in 2015) to under 500,000 deaths (by 2030)

Countries on Track for 2030 Goal:

- Australia
- France
- Iceland
- Italy
- Japan
- South Korea
- Spain
- Switzerland
- United Kingdom
- Egypt
- Georgia
- Mongolia

What about the United States???
When will the United States achieve the WHO’s elimination targets for hep C?

*The estimation may be less accurate owing to the small number of HCV patients in the area. HCV, hepatitis C virus.*

Sulkowski et al., 2021.
HCV Elimination: Direct-acting antivirals (DAAs)

DAA’s = Cornerstone of HCV elimination
HCV Elimination: Direct-acting antivirals (DAAs)

We have the muscle...
So how do we flex???
HCV Elimination: Micro-Elimination

- Reduces HCV incidence, prevalence, and mortality by tailoring health services to overcome barriers.

- Breaks down national elimination goals into smaller goals for individual population segments/groups

- Allows for treatment and prevention interventions to be delivered more quickly and efficiently

(Lazarus et.al., 2017).
HCV Elimination: Micro- Elimination

Successful Micro-Elimination in Egypt

From June 2016-18 → 12-80 yo in 63 villages in 7 governates of Egypt were tested and treated

<table>
<thead>
<tr>
<th>Component</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCV Ab+</td>
<td>29,533</td>
<td>100%</td>
</tr>
<tr>
<td>RNA Tested</td>
<td>29,533</td>
<td>100%</td>
</tr>
<tr>
<td>HCV RNA+</td>
<td>15,139</td>
<td>51%</td>
</tr>
<tr>
<td>HCV RNA+</td>
<td>15,139</td>
<td>100%</td>
</tr>
<tr>
<td>Treated</td>
<td>13,017</td>
<td>86%</td>
</tr>
<tr>
<td>SVR</td>
<td>12,615</td>
<td>83%</td>
</tr>
</tbody>
</table>

Key Components

- Community mobilization
- Free testing (reflex RNA)
- Linkage to care
- Free treatment
- Education campaign
- Prevention

Ongoing immense screening program: 45 million people tested in 6 months

HCV Elimination: 3-Pronged Approach

CRITICAL TO ANY HCV ELIMINATION PROGRAM

• Harm Reduction
  - Syringe Exchange Programs
  - PWID account for 75% of new HCV cases
  - Helps reduce the transmission of HCV

• Addiction Care
  - Medication Assisted Therapy
  - Counseling Services

• HCV Treatment
  - Emphasis on PWID
HCV Elimination: Harm Reduction

Medication Assisted Treatment

2009 vs 2021

HCV Elimination: Barriers to Micro-Elimination

• “…especially critical for risk groups because the greatest obstacles to HCV control are the challenging social realities of those most affected by the disease.”

• Marginalized populations or sub-populations (i.e. PWID) are difficult to diagnose and link to care.

• Not a “one-size-fits-all” approach

• Data monitoring and improvement is CRITICAL!! Most countries don’t have accurate epidemiology data to assess potential populations for micro-elimination.

“The entire hepatitis elimination effort, micro- or otherwise, depends on improving the availability of reliable data to describe the epidemiology of HCV in a country.”

(Lazarus et.al., 2017)
HCV Elimination: Other Barriers

• Lack of awareness of HCV status
• Access to screening
• Stigma and discrimination
• Lack of SEP
• National elimination plan in the US does not exist
• Missed opportunities
HCV Elimination: States with plans
What is Kentucky doing to eliminate hep C?
HCV Elimination Opportunities: Incarcerated Population

Hep C Antibody Prevalence

Hep C Screening at Intake
that is: Routine; Universal (Opt-out or Mandatory); since 2017

Kentucky
The state has a HCV prevalence in its prison population of 15.5%. Data were last updated in 2017-2018. Data source: STK.

HCV Elimination Opportunities: Incarcerated Population

Hep C Treatment

BOP Guidelines on HCV infection as of September 2018

Kentucky

% treated per year: 1.27%
(of those infected)
% persons with viremia: 11.63%

This state treated at least 34 people out of an estimated 2676 treatment candidates (1.27%) in FY2017.

Data source: Siraphob Thanthong-Knight

Appeals Court Upholds Rationing of Hepatitis C Treatment

The Kentucky Department of Corrections can deny a life-saving but expensive hepatitis C medication to inmates.

By Associated Press | July 10, 2021, at 11:18 a.m.

CINCINNATI (AP) — The Kentucky Department of Corrections can deny a life-saving but expensive hepatitis C medication to inmates, a federal appeals court ruled in a split decision. The dissenting judge in last week’s 2-1 ruling at the 6th U.S. Circuit Court of Appeals said the majority’s opinion will condemn hundreds of prisoners to long-term organ damage and suffering, The Courier-Journal reported.

Hepatitis C is the leading cause of liver transplantation and serious liver disease, including cirrhosis and liver cancer, and Kentucky has the highest infection rate in the United States. Newer treatments can cure nearly 100% of patients but cost $13,000 to $32,000. Because they cost so much, the Kentucky Department of Corrections has restricted use of the treatment to inmates with advanced liver scarring, or fibrosis.
HEPATITIS C INFECTED PREGNANT WOMEN: FACTORS ASSOCIATED WITH LINKAGE-TO-CARE AFTER DELIVERY

Barbra Cave, PhD, APRN1; Kristin Higdon, RN2; Natalie Pasquesi, RN, MBA1; Claudia Espinosa, MSc, MD2
1University of Louisville, Louisville, KY; 2University of South Florida, Tampa, FL

INTRODUCTION
Hepatitis C virus (HCV) infections have been increasing in women of childbearing age, especially in Appalachian United States1. HCV can be transmitted from mother-to-baby during pregnancy2.
• Kentucky was the first state to mandate HCV screening in pregnant women3.
With increasing identification of HCV infected pregnant women, the University of Louisville (UofL) sought to develop a registry to enable a nurse-led linkage-to-care navigation program for both mothers and infants. Linkage-to-care is attending a first appointment with:
  • Primary care provider
  • Hepatitis care provider
  • Mental health provider
  • Addiction care provider

The specific aims of this study were to 1) describe demographic factors such as age, ethnicity, substance use status, hepatitis C exposure or infection status, and insurance status for antepartum women; 2) and to determine if these factors correlate with the likelihood of linkage-to-care.

METHODS
Secondary data analysis of the de-identified registry utilized univariate and bivariate statistics using SPSS version 25. Chi square and stratified chi square analysis was used to determine what relationships among variables were present. Data were collected January 2018-April 2019. The study was IRB approved as non-human subjects research.

RESULTS
97 HCV antibody positive women delivered during the study period:
• 89 (91.8%) had HCV RNA detected
Demographics for HCV Infected Mothers:
• 88% (n=78) were white, 12 % were black (n=11)
• 77.3% (n=75) were not married
• 80.4% (n=78) had Medicaid insurance
• 25.8% (n=25) women reported using methamphetamine; 19.8% (n=19) reported using heroin during pregnancy

History of Drug Injection

Smoking Status

82%
19%
74%
26%

● Ever Injected Drugs  Never Injected Drugs  Smoker  Non-smoker

Substance Use During Pregnancy

67%
33%
47%
53%

● Illicit Drug Use  No Illicit Drug Use

• 81.4% (79) of the women linked to care.
• Women newly diagnosed with HCV infection (p=0.012) and/or not receiving prenatal care (p<0.001) were significantly less likely to link-to-care.
• There was no difference in linkage-to-care rate with respect to substance of abuse, current IDU, age, insurance status, marital status, educational attainment, or other factor.

CONCLUSION
• HCV infected postpartum women successfully link-to-care despite history of ongoing substance use, and regardless of substance(s) used.
• Receiving no prenatal care and/or learning of HCV infection at the time of delivery is associated with reduced linkage-to-care
• New strategies for linking women without prenatal care and those newly diagnosed with HCV infection are needed.
• HCV infection in pregnant women in Kentucky is highly associated with any history of injection drug use.

REFERENCES
3. KRS § 214.160

ACKNOWLEDGEMENTS
This work would not have been possible without a Gilead Frontlines of Communities of the United States (FOCUS) grant. The FOCUS grant helped us develop the registry and care navigation process from which the primary data source was created.
HCV Elimination Opportunities: Rural Areas

- Free, peer-based hepatitis C treatment training program for healthcare providers
- Mentorship and advice from hepatitis C treatment experts
- Allows increased access to care in high-risk, low-resource areas of Kentucky
HCV Elimination Opportunities: Hospitalized Population

**UofL Health Inpatient Hep C Consultation Program**

- Consultation service for inpatients with diagnosis of HCV (acute vs. chronic)
- Order placed in EMR by nurse or provider
- Hep C APRN will consult patient while hospitalized
- Provide education on HCV, harm reduction, treatment and cure
- Establish rapport
- Linkage to care
HEPATITIS C EXPOSURE AND OUTCOMES IN YOUNG ADULTS SEEN IN THE EMERGENCY DEPARTMENT

Introduction

Kentucky is a national leader in cases of hepatitis C virus (HCV) infection. The University of Louisville Hospital Emergency Department (ED) implemented a program to increase HCV testing and diagnosis among young adults and linking those with infections to care.

The specific aims are:
1. To estimate the prevalence of HCV Ab and HCV RNA in patients who are aged 18-45 years seen at the ED.
2. To describe demographic factors such as age, ethnicity, substance use status, and insurance status among HCV RNA positive patients in this age group.
3. To determine if these factors correlate with the likelihood of linkage-care.

Methods

The hospital electronic medical record (EMR), Cerner, was modified to task a nurse-administered questionnaire as part of the ED triage process for adults aged 18-45. Patients had to be alert and oriented to complete the questionnaire.

Questionnaire:
1. Have you ever been told you have hepatitis C?
2. Have you ever had any tattoos or body piercings that were placed outside of a licensed business or by an unlicensed professional?
3. Have you ever been exposed to someone else’s blood through your work or recreational activities?
4. Have you ever been told you liver enzymes (or liver tests were elevated)?
5. Have you ever, even just once or a very long time ago, injected or snorted drugs?
6. Have you lived with someone who has been diagnosed with HCV?

The EMR generated an order for HCV Ab for patients meeting the following criteria:
1. Completed ED triage questionnaire with at least one positive indicator
2. Did not opt-out
3. Had blood drawn as part of their care
4. Did not have a result for HCV Ab in the EMR from the past 90 days

Patients with HCV Ab were educated by a navigator on the meaning of the results.

Those with HCV RNA were navigated to care through mental or addiction care services, primary care, or through an HCV treatment specialist.

Following IRB approval, a secondary data analysis on a de-identified database was completed. The database was queried for year of birth, race, ethnicity, gender, insurance status, presence of HCV antibody, HCV RNA status, tobacco use, alcohol use, substance use, incarceration status, linkage-to-care status and the type of organization linked to. Descriptive statistics were explored and chi square tests were performed to examine relationships among the variables.

Results

From 1/2020 through 7/2020, 3530 patients responding to the questionnaire indicated at least one positive indicator 1850 unique individuals completed testing. 638 people were HCV Ab positive, representing a 36.8% HCV exposure rate among those tested. HCV RNA was detected in 436 people, representing an HCV infection prevalence of 23% among those tested. 12.4% prevalence among those with a positive risk indicator, and an overall prevalence of 3.6%. The median age for HCV RNA positive patients was 34 years (IQR 29-39 years). 207 (71.6%) were male. There were no significant associations between gender, insurance status, substance use (including tobacco and alcohol), and incarceration status on HCV Ab or RNA prevalence; however, Black or African American patients were less likely to link-to-care (p=0.048), and those with any type of Medicaid insurance were more likely to link to care (p=0.007) during the study period.

Figure 1

HCV Care Continuum
January through July 2020

<table>
<thead>
<tr>
<th>LINKED TO CARE</th>
<th>46</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCV RNA POSITIVE</td>
<td>436</td>
</tr>
<tr>
<td>HCV RNA COMPLETED</td>
<td>641</td>
</tr>
<tr>
<td>AB POSITIVE</td>
<td>596</td>
</tr>
<tr>
<td>COMPLETED AB TEST</td>
<td>1890</td>
</tr>
<tr>
<td>*ELIGIBLE FOR TESTING</td>
<td>2759</td>
</tr>
<tr>
<td>OPT-OUT</td>
<td>761</td>
</tr>
<tr>
<td>POSITIVE RISK INDICATOR</td>
<td>3530</td>
</tr>
<tr>
<td>QUESTIONNAIRE COMPLETED</td>
<td>12208</td>
</tr>
</tbody>
</table>

*Patients were eligible for testing if they reported at least one risk indicator, did not opt out, had blood drawn as part of the visit, and had not had HCV Ab or PCR testing in the previous 90 days.

CONCLUSIONS

- The ED is an important place to detect HCV Ab and RNA in young adults.
- The rate of HCV exposure among young adults seen in this ED is high.
- Refraining HCV Ab to HCV RNA is a best practice in the HCV care continuum.
- Research exploring factors associated with low rates of Black or African American patients linking to care is needed.
- A substantial time lag exists from the time of HCV diagnosis to linkage-to-care. Further work exploring timelines and factors associated with linkage are needed.

References


Acknowledgments

This work would not have been possible without a Gilead Frontlines of Communities in the United States (FOCUS) grant. The FOCUS grant helped us develop the registry and care navigation process from which the primary data source was created.

Disclosures

Dr. Cave is on the speaker bureau for Abbvie and Gilead. Dr. Cave receives grant funding from Gilead.
HCV Elimination: Can it happen?

“The simple reality is that progress toward the elimination of HCV will not occur at the same pace in all locations and all populations simultaneously. The strategic implementation of micro-elimination campaigns, the public tracking of their progress and the sharing of lessons learned from these efforts can generate the momentum needed for the entire world to achieve the WHO hepatitis C elimination targets by 2030.”

(Lazarus et.al., 2017)
References


Cave et al., 2019. AASLD

Centers for Disease Control and Prevention. Division of Viral Hepatitis. Statistics and Surveillance


Hepvu.org


http://www.hepcorrections.org/


Acknowledgments

Barbra Cave, PhD, APRN- BC
Discussion & Questions